Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies

BACKGROUND: Many clinical trials show no overall benefit. We examined futility analyses applied to trials with different effect sizes. METHODS: Ten randomised cancer trials were retrospectively analysed; target sample size reached in all. The hazard ratio indicated no overall benefit (n 5), or moderate (n 4) or large (n 1) treatment effects. Futility analyses were applied after 25, 50 and 75 % of events were observed, or patients were recruited. Outcomes were conditional power (CP), and time and cost savings. RESULTS: Futility analyses could stop some trials with no benefit, but not all. After observing 50 % of the target number of events, 3 out of 5 trials with no benefit could be stopped early (low CPp15%). Trial duration for two studies could be reduced by 4–24 months, saving d44 000–231 000, but the third had already stopped recruiting, hence no savings were made. However, of concern was that 2 of the 4 trials with moderate treatment effects could be stopped early at some point, although they eventually showed worthwhile benefits. CONCLUSIONS: Careful application of futility can lead to future patients in a trial not being given an ineffective treatment, and should therefore be used more often. A secondary consideration is that it could shorten trial duration and reduce costs. However, studies with modest treatment effects could be inappropriately stopped early. Unless there is very good evidence for futility, it is often best to continue to the planned end